2seventy bio, Inc. (NASDAQ:TSVT) to Post FY2028 Earnings of $2.52 Per Share, Leerink Partnrs Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) – Equities researchers at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for shares of 2seventy bio in a research report issued to clients and investors on Sunday, April 7th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn $2.52 per share for the year, up from their prior forecast of $2.50. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for 2seventy bio’s current full-year earnings is ($1.36) per share.

2seventy bio (NASDAQ:TSVT) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million during the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative return on equity of 59.19% and a negative net margin of 216.73%. During the same quarter last year, the firm posted ($0.60) earnings per share.

TSVT has been the subject of a number of other research reports. Wedbush reaffirmed a “neutral” rating and issued a $5.00 price target on shares of 2seventy bio in a report on Monday, March 18th. TD Cowen restated a “market perform” rating on shares of 2seventy bio in a research note on Wednesday, January 31st. Citigroup lifted their price target on shares of 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday. Finally, SVB Leerink upgraded 2seventy bio from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $5.00 to $18.00 in a report on Wednesday, January 31st. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.17.

2seventy bio Stock Up 2.2 %

2seventy bio stock opened at $5.63 on Tuesday. The company has a market cap of $288.88 million, a P/E ratio of -1.27 and a beta of 1.84. 2seventy bio has a 52-week low of $1.53 and a 52-week high of $12.69. The business has a 50-day simple moving average of $5.27 and a two-hundred day simple moving average of $3.95.

Insiders Place Their Bets

In other 2seventy bio news, Director Casdin Capital, Llc acquired 300,000 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was purchased at an average price of $4.90 per share, for a total transaction of $1,470,000.00. Following the acquisition, the director now owns 1,482,623 shares in the company, valued at approximately $7,264,852.70. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On 2seventy bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its stake in shares of 2seventy bio by 512.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,508,800 shares of the company’s stock worth $19,253,000 after acquiring an additional 3,772,556 shares during the period. State Street Corp purchased a new position in shares of 2seventy bio during the 1st quarter valued at about $53,909,000. Wellington Management Group LLP acquired a new position in shares of 2seventy bio in the 1st quarter valued at about $42,854,000. Newtyn Management LLC boosted its stake in shares of 2seventy bio by 317.0% in the third quarter. Newtyn Management LLC now owns 3,076,490 shares of the company’s stock worth $12,060,000 after buying an additional 2,338,746 shares during the last quarter. Finally, BlackRock Inc. purchased a new stake in shares of 2seventy bio in the first quarter worth about $27,189,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.